Literature DB >> 10456907

Pseudomonas aeruginosa exoenzyme S stimulates murine lymphocyte proliferation in vitro.

N G Barclay1, J C Spurrell, T F Bruno, D G Storey, D E Woods, C H Mody.   

Abstract

The exuberant immunoinflammatory response that is associated with Pseudomonas aeruginosa infection is the major source of the morbidity and mortality in cystic fibrosis (CF) patients. Previous studies have established that an exoproduct of P. aeruginosa (exoenzyme S) is a mitogen for human T lymphocytes and activates a larger percentage of T cells than most superantigens, which may contribute to the immunoinflammatory response. An animal model would facilitate studies of the pathophysiologic consequences of this activation. As a first step toward developing an animal model, the murine lymphocyte response to exoenzyme S was examined. When stimulated with exoenzyme S, splenocytes isolated from naive mice entered S phase and proliferated. The optimum response occurred after 2 to 3 days in culture, at 4 x 10(5) cells per well and 5.0 micrograms of exoenzyme S per ml. The response was not due to lipopolysaccharide, since Rhodobacter sphaeroides lipid A antagonist did not block the response. Other preparations of exoenzyme S stimulated lymphocyte proliferation, since the response to recombinant exoenzyme S (rHisExo S) cloned from strain 388 was similar to the response to exoenzyme S from strain DG1. There was evidence that genetic variability influenced the response, since A/J, CBA/J, and C57BL/6 mice were high responders and BALB/cJ mice were low responders following stimulation with exoenzyme S. Both splenic T and B lymphocytes entered the cell cycle in response to exoenzyme S. Thus, murine lymphocytes, like human lymphocytes, respond to P. aeruginosa exoenzyme S, which supports the development of a murine model that may facilitate our understanding of the role that exoenzyme S plays in the pathogenesis of P. aeruginosa infections in CF patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456907      PMCID: PMC96785     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

1.  The role of exoenzyme S in infections with Pseudomonas aeruginosa.

Authors:  T I Nicas; J Bradley; J E Lochner; B H Iglewski
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

2.  Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro.

Authors:  M D Sadick; R M Locksley; C Tubbs; H V Raff
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

3.  Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets.

Authors:  R M Locksley; F P Heinzel; M D Sadick; B J Holaday; K D Gardner
Journal:  Ann Inst Pasteur Immunol       Date:  1987 Sep-Oct

4.  Use of transposon mutants to assess the role of exoenzyme S in chronic pulmonary disease due to Pseudomonas aeruginosa.

Authors:  D E Woods; P A Sokol
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

5.  Role of exoenzyme S in chronic Pseudomonas aeruginosa lung infections.

Authors:  T I Nicas; D W Frank; P Stenzel; J D Lile; B H Iglewski
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

6.  Alteration of pulmonary structure by Pseudomonas aeruginosa exoenzyme S.

Authors:  D E Woods; W S Hwang; M S Shahrabadi; J U Que
Journal:  J Med Microbiol       Date:  1988-06       Impact factor: 2.472

7.  Strain-dependent protective effect of adult thymectomy on murine infection by Mycobacterium lepraemurium.

Authors:  M A Bach; A Hoffenbach
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

8.  Purification of Pseudomonas aeruginosa exoenzyme S.

Authors:  D E Woods; J U Que
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.609

9.  Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon.

Authors:  C Jupin; S Anderson; C Damais; J E Alouf; M Parant
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  5 in total

1.  Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis.

Authors:  Giovanni Di Bonaventura; Arianna Pompilio; Roberta Zappacosta; Francesca Petrucci; Ersilia Fiscarelli; Cosmo Rossi; Raffaele Piccolomini
Journal:  Infect Immun       Date:  2010-03-22       Impact factor: 3.441

2.  Pre-transplant Panel Reactive Antibody and Survival in Adult Cystic Fibrosis Patients After Lung Transplantation.

Authors:  Don Hayes; Dmitry Tumin; Joseph D Tobias
Journal:  Lung       Date:  2016-03-02       Impact factor: 2.584

3.  The heat shock proteins, Hsp70 and Hsp83, of Leishmania infantum are mitogens for mouse B cells.

Authors:  Ana I Rico; Núria Gironès; Manuel Fresno; Carlos Alonso; Jose M Requena
Journal:  Cell Stress Chaperones       Date:  2002-10       Impact factor: 3.667

Review 4.  The impact of host genetic background in the Pseudomonas aeruginosa respiratory infections.

Authors:  Nicola Ivan Loré; Cristina Cigana; Barbara Sipione; Alessandra Bragonzi
Journal:  Mamm Genome       Date:  2018-06-12       Impact factor: 2.957

5.  The ADP-ribosyltransferase domain of the effector protein ExoS inhibits phagocytosis of Pseudomonas aeruginosa during pneumonia.

Authors:  Stephanie M Rangel; Latania K Logan; Alan R Hauser
Journal:  MBio       Date:  2014-06-10       Impact factor: 7.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.